Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

NCT06310824 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: MAB-22
DRUG: EU-Prolia®
DRUG: US-Prolia®

Sponsor

Xentria, Inc.